CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL EMPLOYMENT AGREEMENTEmployment Agreement • March 3rd, 2022 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of March 5, 2021 by and between Passage BIO, Inc. (the “Company”), and Eliseo Oreste Salinas (the “Employee”) (collectively, the “Parties”).
AMENDMENT No. 6 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENTPassage BIO, Inc. • March 3rd, 2022 • Biological products, (no disgnostic substances)
This AMENDMENT No. 6 to the Amended and Restated Research, Collaboration and License Agreement dated May 5, 2020 is entered into as of November 12, 2021 (the “Amendment No. 6 to Restated Agreement Effective Date”) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage” or “Licensee”) with offices at 2005 Market St, 39th Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104 (“Penn”) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, Amendment No. 3 dated December 9, 2020, Amendment No.4 dated June 2, 2021, and Amendment No. 5, dated August 2, 2021 (the “Restated Agreement”). Passage and Penn are referred to collectively as the “Pa
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSEDPassage BIO, Inc. • March 3rd, 2022 • Biological products, (no disgnostic substances)
This AMENDMENT No. 4 to the Amended and Restated Research, Collaboration and License Agreement dated May 5, 2020 is entered into as of June 2, 2021 (the “Amendment No. 4 to Restated Agreement Effective Date”) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage”) with offices at One Commerce Square, 2005 Market St, 39th Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104 (“Penn”) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, and Amendment No. 3 dated December 9, 2020 (the “Restated Agreement”). Passage and Penn are referred to collectively as the “Parties” and individually as a “Party.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIALRestrictive Covenant Agreement • March 3rd, 2022 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This letter confirms the agreement (“Agreement”) between you and Passage Bio, Inc. (the “Company”) concerning the terms of your transition and the termination of your employment with the Company without Cause (as defined in the Amended and Restated Employment Agreement that you entered into with the Company on November 12, 2018, as amended, attached hereto as Exhibit A (the “Employment Agreement”). If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSEDPassage BIO, Inc. • March 3rd, 2022 • Biological products, (no disgnostic substances)
This AMENDMENT No. 7 to the Amended and Restated Research, Collaboration and License Agreement is entered into as of December 3, 2021 (the “Amendment No. 7 Effective Date”) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage” or “Licensee”) with offices at 2005 Market St, 39th Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104 (“Penn”) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020, as amended by the Amendment No.1 dated August 13, 2020, Amendment No. 2 dated November 2, 2020, Amendment No. 3 dated December 9, 2020, Amendment No.4 dated June 2, 2021, Amendment No. 5, dated August 2, 2021, and Amendment 6, dated November 12, 2021 (the “Restated Agreement”). Passage and Penn are referred to collectively as the “Parti
